In a genome-wide CRISPR screen performed on multiple NSCLC cell lines bearing different driver mutations and treated with different targeted therapies, Krall and colleagues [50] identified KEAP1 loss as a key regulator of resistance to multiple targeted therapies, including erlotinib in EGFR mutant NSCLC cells. This evidence concerns the gene EGFR and non-small cell lung carcinoma.